SAN DIEGO, Nov. 20, 2012 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that its Chairman and CEO, Robert Stockman, is presenting at the 24th Annual Piper Jaffray Healthcare Conference at 2:30 p.m. US EST on Tuesday, November 27, 2012. The conference is being held November 27 and 28, 2012, at The New York Palace in New York City.
The information contained in the presentation has been previously disclosed. Copies of REVA's public presentations, which include recent disclosures, may be accessed under the Investor Relations section of the REVA website at www.revamedical.com.
About REVA
REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. REVA's initial product, the ReZolveÒscaffold, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold.
The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505